



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

October 20, 2020: 5:00 – 8:30 p.m.

- **Executive Session** **5:00 - 6:00**

- **Introductions and Approval of DUR Board Minutes** **6:00 - 6:05**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:05 - 6:10**

- **Medical Director Update** **6:10 - 6:15**

- **Proposed 2021 DURB Meeting Schedule** **6:15- 6:20**

- **Follow-up Items from Previous Meetings** **6:20 - 6:20**
 - None at this time

- **RetroDUR/ProDUR** **6:20- 6:30**
 - Introduce: Chantix Use

- **Clinical Update: Drug Reviews** **6:30-6:30**
(Public comment prior to Board action)

Biosimilar Drug Reviews
 - None at this time.
Full New Drug Reviews
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - None at this time

- **New Managed Therapeutic Drug Classes** **6:30 -6:50**
(Public comment prior to Board action)
 - Antiretrovirals**Speaker:** Nicole Trask, PharmD, Scientific Account Lead
Janssen Scientific Affairs. Symtuza

- **Therapeutic Drug Classes – Periodic Review** **6:50 – 6:50**
(Public comment prior to Board action)
 - None at this time

- **Review of Newly Developed/Revised Criteria** **6:50 – 8:20**
(Public comment prior to Board action)

(All changes will be effective January 1, 2021)
 - ADHD/Amphetamine ER

- ADHD/Methylphenidate ER

Speaker: Ryan Gregg, PhD, Medical Science Liaison
Ironshore Pharmaceuticals
Jornay PM (ADHD/Methylphenidate ER category)

- Antidiabetics: GLP-1 RA

Speaker: Niki Patel, PharmD, Medical Account Associate Director
Novo Nordisk, Rybelsus

- Antidiabetics: SGLT-2 Inhibitors
- Antivirals: Influenza Agents

Speaker: Nikhil Kacker, Healthcare Director or Todd Michael, Medical Affairs Executive
Director, Genentech. Xofluza (baloxavir marboxil)

- Antipsychotics: Long Acting Injectables

Speaker: Jane Guo, PharmD, Managed Market Liaison
Otsuka, Abilify Maintena

- Antihyperlipidemics: PCSK9 Inhibitors
- Cardiovascular: Heart Failure

Speaker: Beth D'Ambrosio, PharmD, Regional Medical Science Liaison, Director
Novartis Pharmaceuticals Corporation, Entresto

- Endometriosis-

Speaker: Franco Coranranco Casagrande, Pharm. D Medical Outcomes Science Liaison, Abbvie.
Orilissa.

- HAE
- Hematopoietics: ITP, Platelet stimulating agents
- Hypoglycemia Treatments
- Monoclonal Antibodies: Anti-IL and Anti IgE (products on our PDL as Immunologic Therapies for asthma)

Speaker: Nikhil Kacker, Healthcare Director or Todd Michael, Medical Affairs Executive
Director, Genentech. Xolair® (omalizumab)

- Migraine Therapy: Preventative

Speakers:
Gene Muise, Rph, Senior Health Outcomes & Pharmacoeconomics Specialist
Amgen, Aimovig

Paul Isikwe, PharmD
Medical Outcomes, Northern American Medical Affairs
Teva , AJOVY

- Narcolepsy Agents
- Neurotoxins
- Progestins
- Pulmonary Arterial Hypertension
- Respiratory: Beta Agonists
- Respiratory: Corticosteroids and combinations
- Sickle Cell Anemia Agents
- Vaginal anti-infectives

▪ **General Announcements**

8:20 – 8:30

Benadryl (diphenhydramine): Drug Safety Communication - Serious Problems with High Doses of the Allergy Medicine

https://www.fda.gov/safety/medical-product-safety-information/benadryl-diphenhydramine-drug-safety-communication-serious-problems-high-doses-allergy-medicine?utm_medium=email&utm_source=govdelivery

Invokana, Invokamet, Invokamet XR (canagliflozin): MedWatch Safety Alert - Boxed Warning about Risk of Leg and Foot Amputations Removed

https://www.fda.gov/safety/medical-product-safety-information/invokana-invokamet-invokamet-xr-canagliflozin-medwatch-safety-alert-boxed-warning-about-risk-leg-and?utm_campaign=FDA%20MedWatch%20-%20Invokana%2C%20Invokamet%2C%20Invokamet%20XR%20%28canagliflozin%29%3A%20MedWatch%20Safety%20Alert&utm_medium=email&utm_source=Eloqua

▪ **Adjourn**

8:30